GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cinclus Pharma Holding AB (OSTO:CINPHA) » Definitions » ROC %

Cinclus Pharma Holding AB (OSTO:CINPHA) ROC % : -528.43% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cinclus Pharma Holding AB ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cinclus Pharma Holding AB's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -528.43%.

As of today (2024-12-12), Cinclus Pharma Holding AB's WACC % is 8.44%. Cinclus Pharma Holding AB's ROC % is -175.20% (calculated using TTM income statement data). Cinclus Pharma Holding AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cinclus Pharma Holding AB ROC % Historical Data

The historical data trend for Cinclus Pharma Holding AB's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cinclus Pharma Holding AB ROC % Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23
ROC %
-696.14 -1,271.27 -244.03

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only - -111.95 -100.88 -165.66 -528.43

Cinclus Pharma Holding AB ROC % Calculation

Cinclus Pharma Holding AB's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-200.281 * ( 1 - -0.24% )/( (23.64 + 140.897)/ 2 )
=-200.7616744/82.2685
=-244.03 %

where

Cinclus Pharma Holding AB's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-156.592 * ( 1 - -0.35% )/( (32.897 + 26.577)/ 2 )
=-157.140072/29.737
=-528.43 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cinclus Pharma Holding AB  (OSTO:CINPHA) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cinclus Pharma Holding AB's WACC % is 8.44%. Cinclus Pharma Holding AB's ROC % is -175.20% (calculated using TTM income statement data). Cinclus Pharma Holding AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cinclus Pharma Holding AB ROC % Related Terms

Thank you for viewing the detailed overview of Cinclus Pharma Holding AB's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cinclus Pharma Holding AB Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company's main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.

Cinclus Pharma Holding AB Headlines

No Headlines